The Inotrope Evaluation and Research Patient Registry



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:3/15/2019
Start Date:August 25, 2014
End Date:August 2020
Contact:L. Allyson Checkley, PhD
Email:laura.checkley@CoramHC.com
Phone:303-672-8888

Use our guide to learn which trials are right for you!

Inotrope, Evaluation and Research (INTERPRET) Patient Registry Program

The INTERPRET Inotrope Evaluation and Research Patient Registry is a longitudinal,
observational study designed to look at the demographics and outcomes of heart failure
patients on inotropic therapy administered in the home or infusion suite setting. The data
gathered in this registry will provide information on how a patient's quality of life and
symptoms change over time while on inotrope therapy, and help healthcare providers to have a
better understanding of the benefits and risks associated with bridge-to-treatment and
palliative care.

Eligible patients will be consented by the site investigator or staff to participate in the
Registry at the time of referral for home care. Clinical data, including dosing, symptom
severity, lab values, and hospitalizations, along with data on quality-of-life and patient
compliance with treatment, will be collected by the home care nurses and pharmacists. The
Registry's goal is to significantly contribute to the medical understandings of heart failure
treatment and to improve the quality of care for heart failure patients in the United States
through active publication of registry findings and disease management approaches.

Inclusion Criteria:

- Patient must be prescribed inotropic treatment (milrinone, dobutamine or dopamine)

- Patient must be referred to Coram for this treatment in an alternate site of care,
either home or infusion suite

- Patient must be willing to receive care and comply with the teaching and training
necessary to administer treatment

- Patient is age 18 or over

Exclusion Criteria:

- Patient is unable to start, or stops taking, inotropic medication

- Patient and/or patient insurance will not cover cost of home inotropic treatment with
Coram, or patient elects not to start treatment

- Patient is under the age of 18
We found this trial at
4
sites
Kansas City, Kansas
Principal Investigator: Andrew Sauer, MD
Phone: 913-588-9679
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Jonathan Rich, MD
Phone: 312-926-5164
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Milwaukee, Wisconsin 53215
Principal Investigator: Vinay Thohan, MD
Phone: 414-385-2432
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Maryjane A Farr, MD
?
mi
from
New York, NY
Click here to add this to my saved trials